IDEAS home Printed from https://ideas.repec.org/a/plo/pone00/0228101.html
   My bibliography  Save this article

Genetic polymorphism in C3 is associated with progression in chronic kidney disease (CKD) patients with IgA nephropathy but not in other causes of CKD

Author

Listed:
  • Sara T Ibrahim
  • Rajkumar Chinnadurai
  • Ibrahim Ali
  • Debbie Payne
  • Gillian I Rice
  • William G Newman
  • Eman Algohary
  • Ahmed G Adam
  • Philip A Kalra

Abstract

Objectives: The R102G variant in complement 3 (C3) results in two allotypic variants: C3 fast (C3F) and C3 slow (C3S). C3F presents at increased frequency in patients with chronic kidney disease (CKD), our aim is to explore its role in CKD progression and mortality. Methods: Delta (Δ) eGFR for 2038 patients in the Salford Kidney Study (SKS) was calculated by linear regression; those with ≤-3ml/min/1.73m2/yr were defined as rapid progressors (RP) and those with ΔeGFR between -0.5 and +1ml/min/1.73m2/yr, labelled stable CKD patients (SP).A group of 454 volunteers was used as a control group. In addition, all biopsy-proven glomerulonephritis (GN) patients were studied regardless of their ΔeGFR. R102G was analysed by real-time PCR, and genotypic and allelic frequencies were compared between RP and SP along with the healthy control group. Results: There were 255 SP and 259 RP in the final cohort. Median ΔeGFR was 0.07 vs. -4.7 ml/min/1.73m2/yr in SP vs. RP. C3F allele frequency was found to be significantly higher in our CKD cohort (25.7%) compared with the healthy control group (20.6%); p = 0.008.However, there was no significant difference in C3F allele frequency between the RP and SP groups. In a subgroup analysis of 37 patients with IgA nephropathy in the CKD cohort (21 RP and 16 SP), there was a significantly higher frequency of C3F in RP 40.5% vs. 9.4% in SP; p = 0.003. In the GN group, Cox regression showed an association between C3F and progression only in those with IgA nephropathy (n = 114);HR = 1.9 (95% CI 1.1–3.1; p = 0.018) for individuals heterozygous for the C3F variant, increased further for individuals homozygous for the variant, HR = 2.8 (95% CI 1.2–6.2; p = 0.014). Conclusion: The C3 variant R102G is associated with progression of CKD in patients with IgA nephropathy.

Suggested Citation

  • Sara T Ibrahim & Rajkumar Chinnadurai & Ibrahim Ali & Debbie Payne & Gillian I Rice & William G Newman & Eman Algohary & Ahmed G Adam & Philip A Kalra, 2020. "Genetic polymorphism in C3 is associated with progression in chronic kidney disease (CKD) patients with IgA nephropathy but not in other causes of CKD," PLOS ONE, Public Library of Science, vol. 15(1), pages 1-16, January.
    • Handle: RePEc:plo:pone00:0228101
    DOI: 10.1371/journal.pone.0228101
    as

    Download full text from publisher

    File URL: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0228101
    Download Restriction: no
    File URL: https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0228101&type=printable
    Download Restriction: no
    File URL: https://libkey.io/10.1371/journal.pone.0228101?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Bert J. C. Janssen & Agni Christodoulidou & Andrew McCarthy & John D. Lambris & Piet Gros, 2006. "Structure of C3b reveals conformational changes that underlie complement activity," Nature, Nature, vol. 444(7116), pages 213-216, November.
    2. Cristian Pattaro & Anna Köttgen & Alexander Teumer & Maija Garnaas & Carsten A Böger & Christian Fuchsberger & Matthias Olden & Ming-Huei Chen & Adrienne Tin & Daniel Taliun & Man Li & Xiaoyi Gao & Ma, 2012. "Genome-Wide Association and Functional Follow-Up Reveals New Loci for Kidney Function," PLOS Genetics, Public Library of Science, vol. 8(3), pages 1-15, March.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Hagen Sülzen & Jakub Began & Arun Dhillon & Sami Kereïche & Petr Pompach & Jitka Votrubova & Farnaz Zahedifard & Adriana Šubrtova & Marie Šafner & Martin Hubalek & Maaike Thompson & Martin Zoltner & S, 2023. "Cryo-EM structures of Trypanosoma brucei gambiense ISG65 with human complement C3 and C3b and their roles in alternative pathway restriction," Nature Communications, Nature, vol. 14(1), pages 1-18, December.
    2. Francisco J. Fernández & Jorge Santos-López & Rubén Martínez-Barricarte & Javier Querol-García & Héctor Martín-Merinero & Sergio Navas-Yuste & Martin Savko & William E. Shepard & Santiago Rodríguez de, 2022. "The crystal structure of iC3b-CR3 αI reveals a modular recognition of the main opsonin iC3b by the CR3 integrin receptor," Nature Communications, Nature, vol. 13(1), pages 1-16, December.
    3. Pascal Schlosser & Adrienne Tin & Pamela R. Matias-Garcia & Chris H. L. Thio & Roby Joehanes & Hongbo Liu & Antoine Weihs & Zhi Yu & Anselm Hoppmann & Franziska Grundner-Culemann & Josine L. Min & Ade, 2021. "Meta-analyses identify DNA methylation associated with kidney function and damage," Nature Communications, Nature, vol. 12(1), pages 1-16, December.
    4. Sara L Van Driest & Tracy L McGregor & Digna R Velez Edwards & Ben R Saville & Terrie E Kitchner & Scott J Hebbring & Murray Brilliant & Hayan Jouni & Iftikhar J Kullo & C Buddy Creech & Prince J Kann, 2015. "Genome-Wide Association Study of Serum Creatinine Levels during Vancomycin Therapy," PLOS ONE, Public Library of Science, vol. 10(6), pages 1-14, June.
    5. Nadia Sukusu Nielsen & Alessandra Zarantonello & Seandean Lykke Harwood & Kathrine Tejlgård Jensen & Katarzyna Kjøge & Ida B. Thøgersen & Leif Schauser & Jesper Lykkegaard Karlsen & Gregers R. Anderse, 2022. "Cryo-EM structures of human A2ML1 elucidate the protease-inhibitory mechanism of the A2M family," Nature Communications, Nature, vol. 13(1), pages 1-15, December.
    6. Christina Lamers & Xiaoguang Xue & Martin Smieško & Henri Son & Bea Wagner & Nadja Berger & Georgia Sfyroera & Piet Gros & John D. Lambris & Daniel Ricklin, 2022. "Insight into mode-of-action and structural determinants of the compstatin family of clinical complement inhibitors," Nature Communications, Nature, vol. 13(1), pages 1-15, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:plo:pone00:0228101. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: plosone (email available below). General contact details of provider: https://journals.plos.org/plosone/ .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.